Spots Global Cancer Trial Database for hearing loss
Every month we try and update this database with for hearing loss cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects | NCT01864291 | Bilateral Heari... | Nucleus 24 (dis... | 18 Months - 17 Years | Massachusetts Eye and Ear Infirmary | |
| Cancer and Hearing Loss Related in Children | NCT02425397 | Cancer in Child... Hearing Loss | Genetic study Genetic study M... | 4 Years - | Assistance Publique - Hôpitaux de Paris | |
| MRI-based Synthetic CT Images of the Head and Neck | NCT06016335 | Imaging of Bony... Hearing Loss Cholesteatoma Sinusitis Head and Neck T... | CT scan MRI scan Synthetic CT sc... | 18 Years - | Amsterdam UMC, location VUmc | |
| Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study | NCT05946577 | Head Cancer Neck Cancer | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment | NCT02381782 | Hearing Loss Cancer | 70 Years - | General Hospital Groeninge | ||
| Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves | NCT02310399 | Hearing Loss, B... | Nucleus ABI541 ... | 18 Months - 21 Years | NYU Langone Health | |
| Biomarker for Patients With Fabry Disease (BioFabry) | NCT02778295 | Angiokeratomas Chronic Kidney ... Ocular Abnormal... Hearing Loss | 2 Months - | CENTOGENE GmbH Rostock | ||
| Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma | NCT05641441 | Vestibular Schw... Ototoxicity | Stereotactic ra... | 18 Years - | University Hospital, Geneva | |
| Refining Information Technology Support for Genetics in Medicine | NCT01225978 | Hypertrophic Ca... Hearing Loss Cancer | GeneInsight Cli... | - | Brigham and Women's Hospital | |
| Intraoperative EABR for Decision Making | NCT03745560 | Vestibular Schw... Hearing Loss | 18 Years - 99 Years | Medical University of Vienna | ||
| Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment | NCT04262336 | Ototoxicity | DB-020 Placebo | 18 Years - | Decibel Therapeutics | |
| A Compassionate Use Program to Provide Access to Sodium Thiosulfate | NCT04132882 | Cisplatin-Induc... | Sodium Thiosulf... | 1 Month - 18 Years | TRPHARM | |
| Screening for Hearing Loss After Childhood Cancer | NCT06036407 | Childhood Cance... Hearing Loss | Hearing test | 18 Years - | University of Bern | |
| SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | NCT01451853 | Lung Cancer Head and Neck C... Hearing Loss Ototoxicity Tinnitus Neuropathy | SPI-1005 Low Do... SPI-1005 Middle... SPI-1005 High D... Placebo | 19 Years - 80 Years | Sound Pharmaceuticals, Incorporated | |
| Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer | NCT04915183 | Hearing Loss Head and Neck C... | Placebo Atorvastatin | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment | NCT04262336 | Ototoxicity | DB-020 Placebo | 18 Years - | Decibel Therapeutics | |
| Hearing Loss and Complaint in Patients With Head and Neck Cancer Treated With Radiotherapy | NCT01102621 | Hearing Loss | 11 Years - 84 Years | Hospital A.C. Camargo | ||
| NIDCD Otolaryngology Clinical Protocol Biospecimen Bank | NCT06303180 | Hearing Loss Head and Neck N... Hearing Disorde... Laryngeal Disea... | 3 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| NAC to Prevent Cisplatin-induced Hearing Loss | NCT02094625 | Neuroectodermal... Liver Neoplasms Osteosarcoma Other Childhood... | N-Acetylcystein... | 1 Year - 21 Years | Children's Hospital Los Angeles | |
| SSNHL in Head & Neck Cancer Patients | NCT04609982 | Hearing Loss | ear plugs | - | Nova Scotia Health Authority | |
| Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors | NCT05582551 | Childhood Cance... | Highlighting Pa... | 7 Years - 17 Years | Washington University School of Medicine | |
| NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing | NCT01969370 | Cancer Cardiovascular ... Neurologic Dysf... Congenital Abno... Hearing Loss | Experimental | - | University of North Carolina, Chapel Hill | |
| Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves | NCT02310399 | Hearing Loss, B... | Nucleus ABI541 ... | 18 Months - 21 Years | NYU Langone Health | |
| NIDCD Otolaryngology Clinical Protocol Biospecimen Bank | NCT06303180 | Hearing Loss Head and Neck N... Hearing Disorde... Laryngeal Disea... | 3 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity. | NCT04291209 | Ototoxic Hearin... | N-Acetyl Cystei... | 18 Years - | Sunnybrook Health Sciences Centre | |
| NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing | NCT01969370 | Cancer Cardiovascular ... Neurologic Dysf... Congenital Abno... Hearing Loss | Experimental | - | University of North Carolina, Chapel Hill | |
| The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD) | NCT03914378 | Head and Neck N... Hearing Loss | 18 Years - | University of Manchester | ||
| NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing | NCT01969370 | Cancer Cardiovascular ... Neurologic Dysf... Congenital Abno... Hearing Loss | Experimental | - | University of North Carolina, Chapel Hill | |
| Study to Evaluate the Safety and Pharmacokinetics of SPI-1005 | NCT01452607 | Hearing Loss Cancer | SPI-1005 Placebo | 19 Years - 50 Years | Sound Pharmaceuticals, Incorporated | |
| Biomarker for Patients With Fabry Disease (BioFabry) | NCT02778295 | Angiokeratomas Chronic Kidney ... Ocular Abnormal... Hearing Loss | 2 Months - | CENTOGENE GmbH Rostock | ||
| Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects | NCT01736267 | Bilateral Heari... | Nucleus 24 (dis... | 18 Years - | Massachusetts Eye and Ear Infirmary | |
| MRI-based Synthetic CT Images of the Head and Neck | NCT06016335 | Imaging of Bony... Hearing Loss Cholesteatoma Sinusitis Head and Neck T... | CT scan MRI scan Synthetic CT sc... | 18 Years - | Amsterdam UMC, location VUmc | |
| Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children | NCT03866460 | Intraocular Ret... Hearing Loss | Distortion prod... | 3 Months - 18 Years | Memorial Sloan Kettering Cancer Center | |
| Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 | NCT00004437 | Neurofibromatos... | Multichannel Au... | 12 Years - | FDA Office of Orphan Products Development | |
| Treatment and Prevention of Middle Ear Morbidity in Head and Neck Cancer Patients Following Radiotherapy | NCT02716376 | Otitis Media Wi... Chronic Otitis ... Hearing Loss | Otovent® | 18 Years - 75 Years | Zealand University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
